APPENDIX B: ACRONYMS

Updated: June 25, 2026
Reviewed: June 25, 2026

General Terms

Acronym	Term
°C	degrees Celsius
°F	degrees Fahrenheit
% v	volume
25-OH-vitamin D	25-hydroxy vitamin D
AAP	American Academy of Pediatrics
ABCG2	adenosine triphosphate–binding cassette subfamily G member 2
ACTH	adrenocorticotropic hormone
AE	adverse effect or adverse event
AHR	adjusted hazard ratio
ALT	alanine aminotransferase
ANC	absolute neutrophil count
app	mobile application
ART	antiretroviral therapy
ARV	antiretroviral
ASCVD	atherosclerotic cardiovascular disease
AST	aspartate aminotransferase
ATI	analytical treatment interruption
AUC	area under the curve
$AUC_{0–12h}$	area under the curve from time zero to 12 hours postdose
AUC_{12h}	12-hour area under the curve
$AUC_{0–24h}$	area under the curve from time zero to 24 hours postdose
AUC_{24h}	24-hour area under the curve
AUC_{inf}	area under the concentration time curve extrapolated to infinity
AUC_{last}	area under the curve to the last measurable concentration
AUC_{tau}	area under the concentration time curve over the dosing interval
AV	atrioventricular
BCRP	breast cancer resistance protein
BIND	bilirubin-induced neurologic dysfunction
BMD	bone mineral density

BMI	body mass index
BSA	body surface area
C_{0h}	pre-dose concentration
C_{12h}	concentration at 12 hours
C_{24h}	concentration at 24 hours
C_{avg}	average plasma concentration
C_{max}	maximum plasma concentration
C_{min}	minimum plasma concentration
C_{tau}	concentration at the end of a dosing interval
C_{trough}	trough concentration
CAR	chimeric antigen receptor
CBC	complete blood count
CD4	CD4 T lymphocyte
CD8	CD8 T lymphocyte
CDC	Centers for Disease Control and Prevention
CEPAC	Cost-Effectiveness of Preventing AIDS Complications, a model
CI	confidence interval
CK	creatine kinase
CMV	cytomegalovirus
CNS	central nervous system
COMB-R	cognitive behavioral therapy and medication management algorithm
Cr	creatinine
CRAFFT	Car, Relax, Alone, Forget, Friends, and Trouble (questionnaire)
CrCl	creatinine clearance
CROI	Conference on Retroviruses and Opportunistic Infections
CT	continuous therapy
CV	cardiovascular *or* coefficient of variation
CVD	cardiovascular disease
CYP	cytochrome P450
CYP2B6	cytochrome P450 family 2 subfamily B member 6
CYP3A	cytochrome P450 3A substrate
DAIDS	Division of AIDS (National Institute of Allergy and Infectious Diseases)
DBS	dried blood spot
DM	diabetes mellitus
DOT	directly observed therapy

DRESS	drug reaction (or rash) with eosinophilia and systemic symptoms
DT	dispersible tablet
DXA	dual energy X-ray absorptiometry
EBV	Epstein-Barr virus
EC	enteric-coated
EC_{50}	half maximal effective concentration
EC_{90}	90% effective concentration
ECG	electrocardiogram
ECMO	extra corporeal membrane oxygenation
EEG	electroencephalogram
eGFR	estimated glomerular filtration rate
EM	erythema multiforme
FCT	film-coated tablet
FDA	U.S. Food and Drug Administration
FDC	fixed-dose combination
FLP	fasting lipid profile
FPG	fasting plasma glucose
G6PD	glucose-6-phosphate dehydrogenase
GA	gestational age
GI	gastrointestinal
GLSM	geometric least squares mean
GM	geometric mean
GMR	geometric mean ratio
gp120	glycoprotein 120
HA	height age
HAV	hepatitis A virus
HBcAB	hepatitis B virus core antibody
HBsAb	hepatitis B virus surface antibody
HBsAg	hepatitis B virus surface antigen
HBV	hepatitis B virus
HCV	hepatitis C virus
HD	high dose
HDL	high-density lipoprotein
HDL-C	high-density lipoprotein cholesterol
Hgb	hemoglobin
HgbA1c	glycosylated hemoglobin

HHS	U.S. Department of Health and Human Services
HIV RNA or HIV-1 RNA	viral load
HLA	human leukocyte antigen
HMG-CoA	3-hydroxy-3-methylglutaryl coenzyme A
HR	hazard ratio
HRSA	Health Resources and Services Administration
HSR	hypersensitivity reaction
HSV	herpes simplex virus
IC_{90}	90% maximal inhibitory concentration
IFPG	impaired fasting plasma glucose
IGRA	interferon gamma release assay
IGT	impaired glucose tolerance
IM	intramuscular
IMT	intima-media thickness
INSTI	integrase strand transfer inhibitor
IQ	inhibitory quotient
IQR	interquartile range
IR	insulin resistance
IRIS	immune reconstitution inflammatory syndrome
IU	international unit
IV	intravenous
IVIG	intravenous immune globulin
LA	long-acting
LAI	long-acting injectable
LBW	low birth weight
LDL	low-density lipoprotein
LDL-C	low-density lipoprotein cholesterol
LFT	liver function test
$\log_{10}$	the logarithm to the base 10
LS	lipodystrophy syndrome *or* lumbar spine
LVH	left ventricular hypertrophy
MCV	mean cell volume
MEMS	medication event monitoring system
N/A	not available or not applicable
NASBA	nucleic acid sequence–based amplification

NAT	nucleic acid test
NHLBI	National Heart, Lung, and Blood Institute
NIH	National Institutes of Health
nM	nanomolar
NNRTI	non-nucleoside reverse transcriptase inhibitor
NPHIV	non-perinatally transmitted HIV
NRTI	nucleoside reverse transcriptase inhibitor
OARAC	Office of AIDS Research Advisory Council
OAT	organic anion transporter
OATP	organic anion transporter polypeptide
OATP1B1	organic anion transporter polypeptide 1B1
OBR	optimized background regimen
OBT	optimized background therapy
OGTT	oral glucose tolerance test
OI	opportunistic infection
OR	odds ratio
P-gp	P-glycoprotein
PA	protein-adjusted
PA-IC_{95}	protein-adjusted 90% maximal inhibitory concentration
the Panel	the Panel on Antiretroviral Therapy and Medical Management of Children Living With HIV
PBMC	peripheral blood mononuclear cell
PCP	*Pneumocystis jirovecii* pneumonia
PCR	polymerase chain reaction
PEPFAR	President's Emergency Plan for AIDS Relief
PG	plasma glucose
PHIV	perinatally acquired HIV
PI	protease inhibitor
PK	pharmacokinetic
POC	point of care
popPK	population PK
PPI	proton pump inhibitor
PR	P wave to onset of atrial depolarization
PR interval	interval between the onset of atrial depolarization to the onset of ventricular depolarization
PrEP	pre-exposure prophylaxis
PWV	pulse wave velocity

QTc	QT corrected for heart rate
RCT	randomized controlled trial
RPG	random plasma glucose
RT-PCR	reverse transcription polymerase chain reaction
SAM	severe acute malnutrition
SBIRT	Screening, Brief Intervention, and Referral to Treatment
SCT	short-cycle therapy
SD	standard deviation
SJS	Stevens-Johnson syndrome
SMR	sexual maturity rating
SMS	short message service
SOC	standard of care
SQ	subcutaneous
STI	sexually transmitted infection
STR	single-tablet regimen
$T_{½}$	half-life
TB	tuberculosis
TBLH	total body less head
TC	total cholesterol
TDM	therapeutic drug monitoring
TEN	toxic epidermal necrolysis
TG	triglyceride
TIC	trauma-informed care
TMA	transcription-mediated amplification
T_{max}	time to reach maximum concentration
U=U	Undetectable = Untransmittable
UGT	uridine diphosphate glucuronosyltransferase
UGT1A	uridine diphosphate-glucuronosyltransferase family 1 member A complex
UGT1A1	uridine diphosphate-glucuronosyltransferase family 1 member A complex 1
ULN	upper limit of normal
v/v	volume per volume
w/v	weight per volume
WHO	World Health Organization
XR	extended release